Best Bets in Biotech  Companies with vaccines and treatments for
HIV and AIDS are among the biotech avenues to explore for
investment, according to Ira Leiderman, managing director for
the life-sciences sector of Tanager Capital Group. He also lists
the humanization of monoclonal antibodies and drug-targeting
among the technologies to watch.  For developments in AIDS, he
cites Vaxgen and Progenics as two companies he likes. For more
general biotech investing, he suggests established names such as
Amgen and Genentech. Then, depending on risk, an investor might
try some companies with products but still no profits, and for a
really long shot, companies with no approved products yet.  He
made these comments in a chat presented Aug. 2 by BusinessWeek
Online on America Online. He was replying to questions from the
audience and from David Shook and Jack Dierdorff of BW Online.
Edited excerpts from the chat follow. A complete transcript of
this chat is available from BW Online on AOL, keyword: BW Talk.
Q: The biote